m+Medelevator.RU
← Поиск публикаций
Vaccines · 2026

CEPI Workshop Report: Applying Disease X Vaccine Library and Knowledge Base Approaches to Severe Fever with Thrombocytopenia Syndrome (SFTS).

Conference ProceedingsНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kitano Mitsutaka, Shim Byoung-Shik, Sasaki Hitoshi, Lovell Jonathan F, Kim V Narry, Kim Rachel, Huang Wei-Chao, Kim Sun Bean, Park Woo-Jung, Bettis Alison A, Lee Keun Hwa, Takamatsu Yuki, Castillo-Olivares Javier, Yoshikawa Rokusuke, Gollihar Jimmy D, Segall-Shapiro Thomas H, Spencer Keith C, Malin Gene, Gerhards Nora M, Brangel Polina, Dalland Lindi, Kwon Soo-Young, Kaneko Satoshi, Morita Kouichi, Song Manki, Endy Timothy

Аннотация

On 9-10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI's Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI's partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты